Identification of differentially expressed genes in a renal cell carcinoma tumor model after endostatin-treatment

Laboratory Investigation

Volumn 84, Issue 11, 2004, Pages 1472-1483

  Van Wijngaarden, Jens ^a   De Rooij, Karien ^a   Van Beek, Ermond ^a   Bernsen, Hans ^b   Que, Ivo ^a   Van Hinsbergh, Victor W M ^c,d   Löwik, Clemens ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TNO   (Netherlands)

Author keywords

Cancer; cbfa1 osf2; Endostatin; Granulocytes; Mirror orientation selection; Suppression subtractive hybridization

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 13; ENDOSTATIN; PIMONIDAZOLE; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOXIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CALPAIN 2 GENE; CANCER INHIBITION; CBFA1 GENE; CELL SELECTION; CONTROLLED STUDY; DIFFERENTIAL EXPRESSED GENE; DISEASE MARKER; DRUG MECHANISM; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GRANULOCYTE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CARCINOMA; MIRROR ORIENTATION SELECTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; OSF2 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUPPRESSION SUBTRACTIVE HYBRIDIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CORE BINDING FACTORS; ENDOSTATINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTES; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION FACTORS;

EID: 8344275870     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700157     Document Type: Article

References (52)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Hanahan D, Folkman J. Pattern and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
3. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
4. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
5. Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999;258:345-352.
6. Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999;18:4414-4423.
7. Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999;59:189-197.
8. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-11726.
9. Sauter BV, Martinet O, Zhang WJ, et al. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000;97:4802-4807.
10. Sacco MG, Cato EM, Ceruti R, et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Therapy 2001;8: 67-70.
11. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999;17:343-348.
12. Yokoyama Y, Dhanabal M, Griffioen AW, et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-2196.
13. Ding I, Sun JZ, Fenton B, et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 2001;61:526-531.
14. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
15. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20: 3792-3803.
16. Eder Jr JP, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-3784.
17. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-231.
18. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20: 3804-3814.
19. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001;98:1024-1029.
20. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-822.
21. Ricard-Blum S, Feraud O, Lortat-Jacob H, et al. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J Biol Chem 2004;279:2927-2936.
22. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003;278:37895-37901.
23. Kim Y, Hwang S, Kim Y, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-27879.
24. Hanai J, Gloy J, Karumanchi SA, et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 2002;158:529-539.
25. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-5413.
26. Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002;519:147-152.
27. Konietzko U, Kuhl D. A subtractive hybridisation method for the enrichment of moderately induced sequences. Nucleic Acids Res 1998;26:1359-1361.
28. Rebrikov DV, Britanova OV, Gurskaya NG, et al. Mirror orientation selection (MOS): a method for eliminating false positive clones from libraries generated by suppression subtractive hybridization. Nucleic Acids Res 2000;28:E90.
29. van der Pluijm G, Lowik C, Papapoulos S. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Cancer Treat Rev 2000;26:11-27.
30. Deckers M, van der Pluijm G, Dooijewaard S, et al. Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. Lab Invest 2001;81:5-15.
31. Kerstens HM, Poddighe PJ, Hanselaar AG. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem 1995;43:347-352.
32. Bernsen HJ, Rijken PF, Peters H, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg 2000;93:449-454.
33. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162: 156-159.
34. Geoffroy V, Corral DA, Zhou L, et al. Genomic organization, expression of the human CBFA1 gene, and evidence for an alternative splicing event affecting protein function. Mamm Genome 1998;9:54-57.
35. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-764.
36. Squier MK, Miller AC, Malkinson AM, et al. Calpain activation in apoptosis. J Cell Physiol 1994;159:229-237.
37. Waterhouse NJ, Finucane DM, Green DR, et al. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ 1998;5:1051-1061.
38. Xie H, Johnson GV. Ceramide selectively decreases tau levels in differentiated PC12 cells through modulation of calpain I. J Neurochem 1997;69:1020-1030.
39. Debiasi RL, Squier MK, Pike B, et al. Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors. J Virol 1999;73:695-701.
40. Wood DE, Thomas A, Devi LA, et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 1998;17:1069-1078.
41. Wood DE, Newcomb EW. Caspase-dependent activation of calpain during drug-induced apoptosis. J Biol Chem 1999;274:8309-8315.
42. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003;100:4766-4771.
43. Bloch W, Huggel K, Sasaki T, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000;14:2373-2376.
44. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-663.
45. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-754.
46. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-764.
47. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-771.
48. Westendorf JJ, Hiebert SW. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. J Cell Biochem 1999;32-33(Suppl): 51-58.
49. Deguchi K, Yagi H, Inada M, et al. Excessive extra-medullary hematopoiesis in Cbfa1-deficient mice with a congenital lack of bone marrow. Biochem Biophys Res Commun 1999;25:352-359.
50. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002;16:267-269.
51. Frieser M, Hallmann R, Johansson S, et al. Mouse polymorphonuclear granulocyte binding to extracellular matrix molecules involves beta 1 integrins. Eur J Immunol 1996;26:3127-3136.
52. van den Berg JM, Mul FP, Schippers E, et al. Beta1 integrin activation on human neutrophils promotes beta2 integrin-mediated adhesion to fibronectin. Eur J Immunol 2001;31:276-284.